Proportional hazards models with random effects to examine centre effects in multicentre cancer clinical trials

Statistical Methods in Medical Research

Volumn 11, Issue 3, 2002, Pages 221-236

  Yamaguchi, T ^a   Ohashi, Y ^a   Matsuyama, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN;

BAYES THEOREM; CANCER; CANCER CENTER; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMMUNITY HOSPITAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HAZARD ASSESSMENT; HUMAN; LEARNING; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAMPLING; SCIENTIFIC LITERATURE; STATISTICAL ANALYSIS; STATISTICAL MODEL; UNIVERSITY HOSPITAL; ARTICLE; EPIDEMIOLOGY; JAPAN; PROPORTIONAL HAZARDS MODEL; STATISTICS;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; HUMAN; JAPAN; MULTICENTER STUDIES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0035987873     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280202sm284ra     Document Type: Review

References (62)

1. Clinical efficacy trials with categorical data
2. ICH harmonized tripartite guideline. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use
3. Guidelines for quality assurance in multicenter trials: A position paper
4. Analysis of data from multiclinic trials
5. Some controversies in planning and analyzing multi-center trials
6. Adjustments of center in multicenter studies: An overview
7. Multicenter clinical trials: Bradford Hill's contributions and some subsequent developments
8. Conduct of cooperative field and clinical trials
9. Problems arising in the analysis of a series of similar experiments
10. Design and analysis of multicenter trials
11. A comparison of frailty models for multivariate survival data
12. The impact of heterogeneity in individual frailty on the dynamics of mortality
13. Generalization and application of frailty models for survival and event data
14. Frailty models for survival data
15. Some recent developments for regression analysis of multivariate failure time data
16. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence
17. Multivariate generalization of the proportional hazards model
18. Incorporating random effects into multivariate relative risk regression models
19. The analysis of event history data: A review of progress and outstanding problems
20. A counting process approach to maximum likelihood estimation in frailty models
21. Semiparametric estimation of random effects using the Cox model based on the EM algorithm
22. Estimating random effects in the Framingham Heart Study
23. Regression with frailty in survival analysis
24. A Bayesian analysis of institutional effects in a multicenter cancer clinical trial
25. A Bayesian hierarchical survival model for the institutional effects in a multi-center cancer clinical trial
26. Investigating centre effects in a multi-centre clinical trial of superficial bladder cancer
27. REML estimation for survival models with frailty
28. Multicenter clinical trials and variance components
29. Approximate inference in generalized linear mixed models
30. An extension of Cox's regression model
31. Penalized likelihood in Cox regression
32. Bayes estimates for the linear model
33. A Monte Carlo method for Bayesian inference in frailty models
34. Hierarchical models for multicenter binary response studies
35. Sampling-based approaches to calculating marginal densities
36. Explaining the Gibbs sampler
37. Modelling complexity: Applications of Gibbs sampling in medicine
38. A Bayesian analysis of bivariate survival data from a multicenter cancer clinical trial
39. Understanding the Metropolis-Hastings algorithm
40. Large hierarchical Bayesian analysis of multivariate survival data
41. Non-parametric Bayesian analysis of survival time data
42. A general framework for random effects survival analysis in the Cox proportional hazards setting
43. Generalizing the results of randomized clinical trials
44. Intercept studies, clinical trials, and cluster experiments: To whom can we extrapolate?
45. Providing clinical evidence of effectiveness for human drug and biological products
46. Tamoxifen for early breast cancer: An overview of the randomised trials
47. Meta-analysis
48. Bayesian methods in meta-analysis and evidence synthesis
49. Summing up evidence: One answer is not always enough
50. An analysis of institutional effects in a multicenter cancer clinical trial: Is it also plausible from the clinicians' point of view?